NCT03502148View on ClinicalTrials.gov

Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

October 27, 2019

Study Completion Date

May 6, 2020

Conditions
Oral Squamous Cell Carcinoma
Interventions
DRUG

PRV111 (Cisplatin Transmucosal System)

Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.

Trial Locations (5)

40207

Advanced ENT and Allergy, Louisville

45267

University of Cincinnati Cancer Institute, Cincinnati

77030

Ben Taub Hospital, Houston

Memorial Hermann Hospital, Houston

77054

The University of Texas Health Science Center School of Dentistry, Houston

Sponsors

Lead Sponsor

Privo Technologies
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Privo Technologies

INDUSTRY

NCT03502148 - Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter